The Case for Transparent Pricing

Relevance: This talking point is highly relevant to the argument that 'Kaina Turėtų Būti Skaidri ir Prieinama'. It highlights how a lack of price transparency in the healthcare system can make it difficult for consumers to understand and compare the actual costs of the care they receive. This aligns with the core premise that prices should be transparent and accessible to the public, which is central to the 'Kaina Turėtų Būti Skaidri ir Prieinama' argument.

Factual Accuracy: This talking point is highly factual. The statement accurately describes the lack of price transparency in the U.S. healthcare system, where consumers often do not know the actual prices of the care they receive before receiving it. This is due to the complexity of the system, with multiple payers negotiating different rates for similar services. This lack of transparency makes it difficult for consumers to understand and compare the costs of healthcare, which is a key argument for why prices should be more transparent and accessible.

Relevance: This talking point is highly relevant to the argument that prices should be transparent and accessible. It identifies specific barriers and challenges that currently limit price and quality transparency, which are key issues that need to be addressed in order to achieve the goal of transparent and affordable pricing. By highlighting these regulatory and contractual obstacles, the point directly supports the argument that prices should be more open and available to consumers.

Factual Accuracy: This talking point is highly factual, accurately identifying several key barriers to meaningful price and quality transparency in healthcare. The examples provided, such as ERISA preemption, contract clauses prohibiting disclosure, and limitations of existing transparency tools, are well-documented challenges that have been extensively discussed and researched. While there may be some nuance or additional context around these issues, the overall accuracy of the statement is strong.

Relevance: This talking point is highly relevant to the argument that 'Kaina Turėtų Būti Skaidri ir Prieinama' (Prices Should Be Transparent and Affordable). It directly addresses key recommendations to improve price and quality transparency, which are central to ensuring prices are accessible and understandable for consumers. Measures like focusing on out-of-pocket costs, improving quality comparison tools, limiting restrictive contract clauses, and requiring cost-effectiveness data would all contribute to greater price transparency and affordability, making this a very pertinent argument for the given debate position.

Factual Accuracy: This talking point is highly factual, as it accurately summarizes several well-established recommendations to improve price and quality transparency in the healthcare and pharmaceutical sectors. The recommendations, such as focusing on out-of-pocket costs, improving quality comparison tools, limiting restrictive contract clauses, and requiring cost-effectiveness data, are supported by evidence and advocated by consumer advocacy groups, policy experts, and regulatory bodies. While the specific implementation details may vary, the overall thrust of the talking point is well-grounded in facts and best practices for enhancing price and quality transparency for consumers.

Relevance: This talking point is highly relevant to the argument that 'Kaina Turėtų Būti Skaidri ir Prieinama' (Prices Should Be Transparent and Accessible). Transparent pricing, as described in the talking point, directly supports the idea that customers should have clear and easy access to information about the total cost and breakdown of what they are paying for. This allows them to make informed decisions and promotes fairness and trust in the pricing process, which are central to the 'Kaina Turėtų Būti Skaidri ir Prieinama' argument.

Factual Accuracy: The talking point provides an accurate and comprehensive description of transparent pricing. It correctly highlights the key elements of transparent pricing, including clear communication of costs, accessibility of information, and open disclosure of the reasons behind the pricing. This aligns well with the core principles of the 'Kaina Turėtų Būti Skaidri ir Prieinama' argument. The only minor limitation is that it does not explicitly mention the potential benefits of transparent pricing, such as enabling informed consumer decisions and promoting trust, which could further strengthen the factual accuracy of the statement. Overall, the talking point is highly factual and well-aligned with the debate topic.

Relevance: This talking point is highly relevant to the argument that 'Kaina Turėtų Būti Skaidri ir Prieinama' (Prices Should Be Transparent and Affordable). Transparent pricing, which eliminates hidden costs and unexpected fees, fosters trust between businesses and consumers by showcasing fairness and integrity. This can enhance a company's competitive advantage, as consumers are more likely to choose businesses that are upfront and honest about their pricing. Transparent pricing is a key element of making prices accessible and affordable for consumers, which is central to the argument that prices should be transparent and affordable.

Factual Accuracy: This talking point is highly factual. The statement accurately reflects the benefits of transparent pricing, including fostering trust between businesses and consumers, eliminating hidden costs and unexpected fees, showcasing fairness and integrity, and enhancing a company's competitive advantage. These claims are well-supported by research and evidence on the importance of pricing transparency. The only minor limitation is that the statement does not explicitly mention the impact of transparent pricing on affordability, which is also a key aspect of the 'Kaina Turėtų Būti Skaidri ir Prieinama' argument.

Relevance: This talking point is highly relevant to the argument that 'Kaina Turėtų Būti Skaidri ir Prieinama'. It directly addresses how transparent pricing in healthcare allows patients to make more informed choices and potentially reduce their expenses, which is a key aspect of the argument that prices should be transparent and accessible. The example provided is a clear and compelling illustration of how transparent pricing can benefit consumers, making this a strong argument in favor of the 'Kaina Turėtų Būti Skaidri ir Prieinama' position.

Factual Accuracy: The statement is highly factual. Transparent pricing in healthcare does allow patients to understand the costs of services and procedures before receiving care, which can enable them to make more informed choices and potentially lower their expenses. This is well-documented in various studies and reports on healthcare pricing transparency. The only minor caveat is that the statement doesn't explicitly mention that transparent pricing may not always lead to lower expenses, as other factors like insurance coverage and negotiated rates can still impact the final cost to the patient. But overall, the statement accurately reflects the benefits of transparent healthcare pricing.

Relevance: This talking point is highly relevant to the argument that 'Kaina Turėtų Būti Skaidri ir Prieinama'. It directly addresses the importance of transparent pricing in e-commerce, where clearly communicating all costs upfront helps build consumer trust and loyalty. This aligns with the core premise that prices should be transparent and accessible, as it prevents hidden fees and unexpected charges that can undermine the customer experience.

Factual Accuracy: This statement is highly factual. The claims made are well-supported by research and industry best practices. Transparent pricing, including clear communication of product prices, shipping costs, and additional fees, has been shown to increase consumer trust and loyalty in e-commerce. Hiding or obfuscating costs can lead to negative customer experiences and perceptions of deception. While there may be some nuance or exceptions, the overall premise that transparent and accessible pricing is beneficial for both businesses and consumers is well-established.

Relevance: This talking point is highly relevant to the argument that 'Kaina Turėtų Būti Skaidri ir Prieinama' (Prices Should Be Transparent and Accessible). Transparent pricing requires companies to be more thoughtful and data-driven in setting their prices, as they need to carefully consider their competitive positioning and the value they offer to customers. This aligns well with the core idea that prices should be transparent and accessible, as it promotes pricing practices that are fair and justified from the customer's perspective.

Factual Accuracy: This talking point is highly factual. Transparent pricing does indeed force companies to be more deliberate and data-driven in their pricing decisions, as they need to carefully benchmark against competitors and ensure their value proposition is clear and justified. This level of transparency and accountability typically leads to more fair and accessible pricing for consumers. The only minor caveat is that the statement could be slightly overstated, as there may be some exceptions where companies can maintain opaque pricing even with transparency. Overall, the core premise is well-supported by evidence and aligns with the argument that prices should be transparent and accessible.

Relevance: This talking point is highly relevant to the argument that prices should be transparent and accessible. The example of SaaS (Software as a Service) pricing models demonstrates how transparent and flexible pricing structures can benefit customers by allowing them to pay only for the resources they actually use. This aligns with the core principles of the 'Kaina Turėtų Būti Skaidri ir Prieinama' argument, as it shows how transparent and scalable pricing can make services more affordable and accessible to customers.

Factual Accuracy: The statement is largely accurate in describing how SaaS pricing models can provide transparent and accessible pricing for customers. The key points about scalable subscription models, pay-as-you-go pricing, and the ability to match capacity to usage needs are well-supported by the realities of modern SaaS offerings. However, the statement could be slightly more nuanced, as there may be some edge cases or additional complexities in how SaaS pricing is structured in practice. Overall, the factual basis of the statement is strong and it provides a relevant example to support the 'Kaina Turėtų Būti Skaidri ir Prieinama' argument.

Relevance: This point is highly relevant to the argument that prices should be transparent and accessible. It highlights how different payers, such as Medicaid and commercial health plans, have different pricing arrangements with drug manufacturers, while self-pay consumers face prices set by individual pharmacies. This demonstrates the lack of transparency and the need for more consistent and accessible pricing information for consumers.

Factual Accuracy: The statement is largely factual, providing accurate information about how different payers, such as Medicaid and commercial health plans, have different pricing arrangements with drug manufacturers, while self-pay consumers face prices set by individual pharmacies. This highlights the lack of transparency in pharmaceutical pricing. However, the statement could be slightly more nuanced, as it does not fully capture the complexities of the pharmaceutical pricing landscape, such as the role of pharmacy benefit managers and the potential impact of rebates and discounts on final consumer prices.

Relevance: This talking point is highly relevant to the argument that 'Kaina Turėtų Būti Skaidri ir Prieinama' (Prices Should Be Transparent and Accessible). It directly addresses the key elements of price transparency, such as providing detailed information about pricing structures, fees, discounts, and cost breakdowns across multiple channels. This level of transparency is essential for ensuring that consumers can make informed decisions and that the pricing is accessible and understandable. Therefore, this talking point strongly supports the argument that prices should be transparent and accessible.

Factual Accuracy: The talking point is largely factual, accurately describing the key elements of effective price transparency, such as providing detailed information about pricing structures, fees, discounts, and cost breakdowns across multiple channels. This level of transparency is widely recognized as important for enabling consumers to make informed decisions. However, the statement could be slightly more precise by acknowledging that the specific implementation details may vary across different industries and contexts.

Relevance: This talking point is highly relevant to the argument that 'Kaina Turėtų Būti Skaidri ir Prieinama' (Prices Should Be Transparent and Affordable). It highlights how price transparency is essential in the manufacturing industry, as it helps build trust with customers and allows them to make informed decisions. This directly supports the idea that prices should be transparent and accessible, as it empowers consumers and fosters a more competitive market.

Factual Accuracy: This statement is highly factual. The claim that price transparency is essential for building trust and staying competitive in machine manufacturing is well-supported. Transparent pricing allows customers to understand the true value of products, make informed decisions, and promotes a more competitive market. While there may be some nuance or exceptions, the overall assertion is accurate and well-grounded in the realities of the manufacturing industry.

Relevance: This talking point is highly relevant to the argument that prices should be transparent and accessible. By highlighting how SaaS models make enterprise software more affordable for organizations with limited IT resources, it demonstrates how transparent and accessible pricing can make advanced technologies more widely available. This supports the core idea that prices should be transparent and affordable, rather than kept confidential.

Factual Accuracy: This talking point is largely factual. It accurately describes how SaaS (Software as a Service) models can make enterprise-level software more affordable and accessible to organizations by eliminating the need to purchase, install, and maintain hardware and software infrastructure. This reduces the upfront and ongoing costs associated with traditional enterprise software deployments, making them more accessible to organizations with limited IT resources. The only minor caveat is that the statement oversimplifies the cost savings, as there are still subscription fees and other ongoing costs associated with SaaS. However, the overall point that SaaS makes enterprise software more affordable is well-supported by the facts.

Relevance: This talking point is highly relevant to the argument that prices should be transparent and accessible. It highlights the fact that there is substantial variation in negotiated prices between public and private payers, which supports the need for greater price transparency. By demonstrating the lack of consistency and clarity in current pricing practices, this point strengthens the case that prices should be more open and understandable to consumers.

Factual Accuracy: The statement is highly factual. It accurately describes the different pricing mechanisms used by public and private payers in the healthcare system. The research evidence on substantial variation in negotiated prices between these payers is well-documented in the academic literature. While there may be some nuance or additional context that could be added, the core claims made in this talking point are supported by reliable data and analysis.

Relevance: This talking point is highly relevant to the argument that 'Kaina Turėtų Būti Skaidri ir Prieinama' (Prices Should Be Transparent and Affordable). The use of market-based pricing, AI-powered intelligence, and competitive benchmarking suggests that the pricing process is data-driven and transparent, which supports the idea of transparent and accessible pricing. Additionally, the mention of dynamic pricing and staying competitive indicates that the pricing is aimed at being affordable and accessible to customers, further strengthening the 'Kaina Turėtų Būti Skaidri ir Prieinama' argument.

Factual Accuracy: The talking point is largely factual, as it accurately describes the use of market-based pricing, AI-powered intelligence, and competitive benchmarking to enable dynamic and transparent pricing. This approach supports the argument that prices should be transparent and accessible. However, the statement does not provide specific details on how this translates to actual affordable pricing for customers, so a factual rating of 8 is appropriate rather than a perfect 10.

Relevance: This talking point is highly relevant to the argument that prices should be confidential. The example of the Medical Research Act in Germany demonstrates how confidential reimbursement contracts can be used to incentivize pharmaceutical R&D, which supports the idea that price confidentiality can have benefits. The point highlights how price transparency may not always be the optimal approach, especially when it comes to encouraging investment and innovation in certain industries.

Factual Accuracy: The talking point provides a fairly accurate description of the Medical Research Act in Germany that aims to allow select manufacturers to enter confidential reimbursement contracts with statutory health insurance payers. The statement about this policy's goal of bolstering Germany's attractiveness as a hub for pharmaceutical R&D is also factually correct. Overall, the information presented appears to be well-grounded in the actual policy details, warranting a high factual rating.

Relevance: This point is fairly relevant to the argument that prices should be confidential. It highlights a key aspect of the confidential pricing model in Germany, where the pre-AMNOG price remains visible but the manufacturer must reimburse the difference to sick funds. This demonstrates how confidential pricing can be implemented in practice, making it a relevant consideration for the overall debate.

Factual Accuracy: This talking point is highly factual. It accurately describes the key aspects of confidential pricing in Germany under the AMNOG system. The statement correctly explains that the pre-AMNOG price remains visible, but the manufacturer must reimburse the difference between that and the confidential price to sick funds, along with any overpaid mandatory surcharges. This is a well-established policy in the German pharmaceutical pricing system, so the factual accuracy of this statement is very high.

Relevance: This point is moderately relevant to the argument that prices should be transparent and accessible. It highlights how SaaS (Software as a Service) can enable a mobile workforce and provide data security without additional in-house expertise. This suggests that SaaS pricing models can make enterprise-level software more accessible to a wider range of organizations, which supports the idea of transparent and affordable pricing. However, the point does not directly address pricing itself, so it is not as strongly relevant as a point that would focus more explicitly on pricing considerations.

Factual Accuracy: The statement is mostly factual, providing accurate information about how SaaS enables mobile access to applications and data, as well as how service providers handle compatibility and security management. This supports the argument that SaaS pricing can be more transparent and accessible compared to traditional enterprise software models that require significant in-house IT expertise and infrastructure. The only minor caveat is that the statement does not directly address pricing itself, so it is not a perfect fit for the specific debate point.

Relevance: This talking point is moderately relevant to the argument that prices should be transparent and accessible. It highlights recent efforts to improve price transparency in the healthcare industry, which is a positive step towards the goal of transparent and accessible pricing. However, the point also acknowledges that the current tools and initiatives have limitations, suggesting that more work is needed to truly achieve the desired level of transparency and accessibility. Overall, this point provides useful context and supports the general argument, but does not fully address the core issues of the debate.

Factual Accuracy: The statement is largely factual, as it accurately reflects the current state of price transparency initiatives in the healthcare industry. The claim that recent federal and state efforts have focused on requiring hospitals to disclose chargemaster data and negotiated rates, as well as providing online price transparency tools, is supported by evidence. Additionally, the acknowledgment that these tools can be difficult to navigate and do not always provide accurate pricing information is also a fair assessment of the limitations of the current transparency efforts. While the statement does not provide a comprehensive picture of the issue, the factual elements it includes are well-supported.

Relevance: This point is highly relevant to the argument that price should be confidential. The discussion of the AMNOG guardrails in Germany and the potential revenue implications through international reference pricing highlights how transparent pricing can put companies at a disadvantage and lead to lower prices. This supports the argument that confidential pricing is necessary to protect the commercial interests of pharmaceutical companies.

Factual Accuracy: The statement about the 2022 AMNOG guardrails in Germany and their impact on pricing is mostly accurate, but it contains some simplifications and lacks important context. While it is true that a 'No Additional Benefit' rating can result in price parity with off-patent comparators, the overall pricing framework under AMNOG is more nuanced and involves negotiations between companies and the G-BA. The potential revenue implications through international reference pricing are also a valid concern, but the degree of impact can vary depending on specific market conditions. Overall, the statement captures some key elements of the pricing dynamics, but a more comprehensive understanding of the AMNOG system and its implications would be needed to fully evaluate the factual accuracy.

Relevance: The provided talking point about the advantages of SaaS (Software as a Service) has some relevance to the argument that prices should be transparent and accessible, but it does not directly address the issue of pricing itself. The talking point focuses more on the technical and operational benefits of the SaaS model, rather than the pricing structure. While these advantages may indirectly support the idea of transparent and accessible pricing, the connection is not strong enough to be considered a highly relevant argument for this specific debate.

Factual Accuracy: The talking point accurately describes the key characteristics and benefits of the SaaS model, such as cloud-based hosting, subscription-based access, ease of use, scalability, and reduced IT infrastructure requirements. These statements are well-aligned with the widely recognized features of SaaS and are supported by industry knowledge and research. The information provided is factually sound, with only minor caveats or nuances that could be added to provide a more complete picture. Overall, the factual accuracy of this talking point is high.

Relevance: This talking point is reasonably relevant to the argument that pricing should be confidential. It highlights a specific scenario where confidential pricing can provide protection for markets that reference Germany's list prices in the International Reference Pricing (IRP) system. This helps mitigate the risk of knock-on effects and revenue loss, which supports the case for confidential pricing in certain situations.

Factual Accuracy: The statement about the 'main opportunity for confidential pricing' being protection for markets that reference Germany in International Reference Pricing (IRP) is generally factual. It accurately describes a specific scenario where confidential pricing can be advantageous to mitigate risks of knock-on effects on net prices and revenue loss in markets that reference Germany's list prices. However, the statement does not provide a comprehensive view of all the potential justifications or use cases for confidential pricing, so the factual rating is not a perfect 10.

Relevance: This talking point is moderately relevant to the argument that pricing should be confidential. It highlights some of the potential risks and challenges that manufacturers may face with transparent pricing, such as unequal investment requirements favoring larger players and the limited timeframe for increased R&D efforts in Germany due to the Sunset Clause. These factors could support the case for confidential pricing to protect manufacturers' competitive positions and incentivize innovation. However, the point does not directly address the core arguments around consumer transparency, trust, or market competition, which are also important considerations in this debate.

Factual Accuracy: This talking point contains some factual information, but also makes some assumptions and generalizations that are not fully supported. The statement about the 'unequal' investment requirements favoring larger manufacturers is plausible, as economies of scale can provide advantages to larger firms. The reference to the Sunset Clause in 2028 and the limited window for increased R&D efforts in Germany is also factually accurate. However, the overall assertion that these factors necessitate confidential pricing is more speculative and requires further evidence and analysis to substantiate. The potential risks and rewards of confidential pricing for manufacturers are complex, and this talking point oversimplifies the issue.

Relevance: The provided talking point about SaaS (Software as a Service) has moderate relevance to the argument that 'Kaina Turėtų Būti Skaidri ir Prieinama' (Prices Should Be Transparent and Affordable). While SaaS can potentially offer more affordable and transparent pricing models compared to traditional software licensing, the talking point does not directly address the specific issue of price transparency and affordability. It focuses more on the general characteristics of the SaaS delivery model. To be more relevant, the talking point would need to provide more direct evidence or arguments about how SaaS pricing structures contribute to price transparency and affordability for consumers.

Factual Accuracy: The provided talking point about SaaS (Software as a Service) is largely factual, accurately describing the key characteristics of this cloud-based software delivery model. The statement correctly explains that SaaS allows individuals or organizations to subscribe to applications rather than purchasing and installing them locally, and that customers access the software over the internet through a web browser while the cloud service provider manages the underlying infrastructure, security, maintenance, and updates. This is an established and well-documented model of software delivery. The only minor caveat is that the statement does not explicitly mention that SaaS pricing is often more transparent and affordable compared to traditional software licensing models, which would make it more directly relevant to the 'Kaina Turėtų Būti Skaidri ir Prieinama' argument.

Relevance: This talking point has moderate relevance to the argument that prices should be transparent and accessible. While it highlights the benefits of SaaS solutions, which can contribute to more affordable and accessible pricing, it does not directly address the issue of price transparency. The point focuses more on the operational and functional advantages of SaaS, rather than the pricing aspects. To be more relevant, the talking point would need to more explicitly discuss how SaaS pricing models, such as subscription-based or pay-as-you-go, can promote transparency and accessibility compared to traditional software licensing.

Factual Accuracy: The statement about SaaS solutions helping organizations streamline operations, enhance collaboration, and improve decision-making is generally accurate. SaaS applications, with their cloud-based delivery and subscription-based pricing models, can provide these benefits to organizations in various industries. However, the statement does not directly address the issue of price transparency and accessibility, which is the focus of the debate. While SaaS pricing models can contribute to more affordable and accessible pricing compared to traditional software licensing, the statement does not explicitly make this connection.

Relevance: This talking point has moderate relevance to the argument that prices should be transparent and accessible. While it discusses the university's investment in online learning, it does not directly address the issue of pricing transparency or accessibility. The point is more relevant to the quality and delivery of online education rather than the specific debate about pricing.

Factual Accuracy: The statement about Ohio University's investment in preparing faculty to deliver effective, student-centered online learning is largely factual. The university's commitment to using the same full-time faculty for both on-campus and online courses, in order to preserve academic continuity and reinforce its commitment to excellence, is a well-established practice in higher education. The details provided in the statement accurately reflect common approaches to ensuring quality and consistency across different course delivery formats.

Relevance: This talking point is reasonably relevant to the argument that prices should be confidential. It suggests that there are specific criteria and requirements that a manufacturer must meet in order to qualify for confidential pricing, implying that confidentiality is tied to certain business practices and investments. This could support the idea that pricing should not be fully transparent, as it may reveal sensitive information about a company's operations and R&D activities.

Factual Accuracy: This statement contains some factual elements, but also makes some unsubstantiated claims. The requirement for a pharmaceutical manufacturer to have an active R&D department in Germany with relevant proprietary projects and collaborations is plausible, as confidential pricing arrangements may be tied to a company's investments and activities. However, the assertion that this is a universal or standard qualification for confidential pricing lacks evidence. The specific criteria for confidential pricing can vary significantly across different markets and regulatory frameworks, so this talking point oversimplifies the process.

Relevance: This talking point has low relevance to the argument that prices should be transparent and accessible. While it discusses some general trends in the SaaS industry, it does not directly address the issue of pricing transparency or accessibility. The points raised, such as the increased use of AI and machine learning, the rise of low-code platforms, and data protection, are more relevant to the overall evolution of the SaaS market rather than the specific debate about pricing.

Factual Accuracy: The statement about key future trends in SaaS, including increased adoption of AI and machine learning, the rise of low-code and no-code platforms, and a greater emphasis on protecting customer data and meeting regulatory requirements, is factually accurate. These are indeed trends that are widely observed and discussed in the SaaS industry. However, the relevance of these trends to the specific debate about whether prices should be transparent and accessible is quite low, as the statement does not directly address pricing or its impact on customers. While the information provided is factually correct, it does not strongly support the argument that prices should be transparent and accessible.

Relevance: This talking point has limited relevance to the argument that 'Kaina Turėtų Būti Skaidri ir Prieinama'. While it discusses program offerings and innovation at Ohio University, it does not directly address the issue of price transparency and affordability. The point focuses more on the academic aspects of the university's programs rather than the financial considerations that are central to the debate.

Factual Accuracy: This talking point has no factual relevance to the debate about price transparency and affordability. It describes program innovation and offerings at Ohio University, which is unrelated to the core issue being discussed.

Relevance: This talking point about Ohio University's online programs is not very relevant to the argument that prices should be transparent and accessible. The point discusses the structure and design of the university's programs, but does not directly address the issue of pricing or accessibility.

Factual Accuracy: This talking point is not very factual in the context of the debate about whether prices should be transparent and accessible. The statement discusses the structure and design of Ohio University's online programs, but does not provide any information about the actual pricing or accessibility of those programs. The factual accuracy of this statement is limited as it does not directly address the key issue being debated.

Relevance: This talking point about Ohio University's online education model has very low relevance to the argument that prices should be confidential. The point does not address pricing or confidentiality at all, and is instead focused on the educational model and offerings of a specific university. It does not provide any meaningful support for the argument that prices should be kept confidential.

Factual Accuracy: This talking point has no factual relevance to the argument that prices should be confidential. It is simply a statement about Ohio University's online education model, which does not address pricing or confidentiality in any way. The statement appears to be completely unrelated to the debate topic.

Relevance: This talking point about Ohio University's online student support infrastructure is not very relevant to the argument that product or service prices should be kept confidential. The information provided is specific to a university's student support model and does not directly address the issue of price transparency versus confidentiality.

Factual Accuracy: This talking point is not at all factual in relation to the argument that product or service prices should be kept confidential. The information provided is about Ohio University's online student support infrastructure, which is completely unrelated to the debate about price transparency versus confidentiality. This talking point does not contain any factual claims relevant to the given debate topic.

Relevance: This talking point about Ohio University's online education model has no relevance to the argument that prices should be confidential. It does not address any aspects of pricing or confidentiality, and is instead focused on the university's educational approach and program development. This information is not relevant to the debate on whether prices should be transparent or confidential.

Factual Accuracy: This talking point has no relevance to the argument that prices should be confidential. It does not contain any factual claims about pricing or confidentiality. Instead, it discusses Ohio University's online education model, which is completely unrelated to the debate topic. As such, this talking point has no factual accuracy that can be evaluated in the context of the given debate.